CD44 and neoplasm: As mentioned above, overexpression of endogenous CD6 ligands (i.e., CD166/ALCAM, CD318/CDCP1, and CD44) is associated with tumour events, so the use of CD6-based CARs may broaden the spectrum of treatable tumours.